Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease.

Long, Richard; Meinhard, E; Skinner, R.K.; Varghese, Z.; Wills, M. R.; Sherlock, Sheila

doi:10.1136/gut.19.2.85

Cited by 156 publications

(61 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although early studies have suggested that disorders of mineralization may be an important component of hepatic osteodystrophy (23)(24)(25), later studies did not reproduce these findings. Indeed, Long et al (23) and Crosbie et al (26) reported that treatment with vitamin D does not prevent the progression of hepatic osteodystrophy in adults.…”

Section: Discussioncontrasting

confidence: 38%

“…Indeed, Long et al (23) and Crosbie et al (26) reported that treatment with vitamin D does not prevent the progression of hepatic osteodystrophy in adults. The present study shows that children and adolescents with CCD have a significant limitation of bone mass development even when their serum 25-OH-D levels are maintained within normal limits.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Longitudinal evaluation of hepatic osteodystrophy in children and adolescents with chronic cholestatic liver disease

Taveira

Pereira

Fernandes

et al. 2010

Braz J Med Biol Res

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 38%

Section: Discussionmentioning

confidence: 99%

Longitudinal evaluation of hepatic osteodystrophy in children and adolescents with chronic cholestatic liver disease

Taveira

Pereira

Fernandes

et al. 2010

Braz J Med Biol Res

View full text Add to dashboard Cite

“…BMD measurements were not routinely performed on patients after transplantation. On the basis of our preliminary observations, beginning in January 1995 all patients with a spine BMD of less than 0.84 g/cm 2 or less than 84% of the predicted value for age and sex were treated with 60 mg intravenous pamidronate disodium (Ciba Laboratories, Horsham, England) every 3 months before and for 9 months after transplantation. An independent t test was used to assess the significance of the difference in BMD between untreated patients who sustained fractures and those who did not.…”

Section: Methodsmentioning

confidence: 99%

Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation

Reeves¹,

et al. 1998

View full text Add to dashboard Cite

Osteoporosis is common in patients with chronic cholestatic liver disease, and atraumatic spinal fracture is a recognized complication after orthotopic liver transplantation. Bisphosphonates are potent inhibitors of osteoclast bone resorption and have been successfully used to treat postmenopausal osteoporosis. We examined whether preoperative bone mineral density can predict the risk of fracture after orthotopic liver transplantation and whether intravenous bisphosphonate can prevent fractures in high-risk patients. Beginning in February 1993, standard bone mineral density measurements of the lumbar spine were performed as part of routine pretransplantation assessment. On the basis of a preliminary analysis from January 1995, patients with a lumbar spine bone mineral density of F0.84 g/cm 2 , or F84% of the predicted value (age/sex), were treated with intravenous bisphosphonate (pamidronate disodium) every 3 months before and for 9 months after liver transplantation. Bone mineral density measurements were available in 90 of 136 consecutive first transplants performed in our unit from February 1993 to September 1996. Before the use of pamidronate, 7 patients sustained symptomatic vertebral fractures. Their mean spine bone mineral density was lower than in the 38 patients with no clinical evidence of fracture (81.8% ؎ 12.3% v 94.2% ؎ 10.2%; P ‫؍‬ .006). Since the introduction of pamidronate, no symptomatic vertebral fractures have occurred. Of 29 surviving patients with bone mineral density F0.84 g/cm 2 before transplantation, 38% who did not receive treatment with pamidronate suffered spontaneous fracture, whereas 0 of 13 who received treatment suffered such a complication. A low lumbar spine bone mineral density is associated with a high risk of symptomatic vertebral fracture after liver transplantation. These results suggest that this risk is considerably reduced by the administration of intravenous bisphosphonate before and after transplantation.

show abstract

“…8 The part that metabolic bone disease might have played in producing rib fractures, however, has not been examined in detail. Various findings suggest that it did not make an important contribution.…”

Section: Discussionmentioning

confidence: 99%

Fractures on the chest radiograph in detection of alcoholic liver disease.

Lindsell¹,

Wilson²,

Maxwell³

1982

BMJ

View full text Add to dashboard Cite

show abstract

Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease.

Cited by 156 publications

References 20 publications

Longitudinal evaluation of hepatic osteodystrophy in children and adolescents with chronic cholestatic liver disease

Longitudinal evaluation of hepatic osteodystrophy in children and adolescents with chronic cholestatic liver disease

Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation

Fractures on the chest radiograph in detection of alcoholic liver disease.

Contact Info

Product

Resources

About